Lymphangiogenesis has received considerable attention and become a new research hotspot of tumor metastasis. Recently, C-C chemokine receptor 7 (CCR7) is known to promote metastasis of non-small cell lung cancer (NSCLC) cells into lymph nodes. In this study, we investigated the relationship between CCL21/CCR7 and the lymphangiogenic factor vascular endothelial growth factor (VEGF)-D in human lu...

Lung cancer is the second most frequent worldwide diagnosed cancer. Mutations in RAS genes family are among common oncogenic alterations occurring non-small cell lung (NSCLC). Many treatment options against KRAS mutations have been developed for NSCLC; however, they remain insufficient. Moreover, role of and HRAS gene expression remains unclear. However, inhibitors seem to be a good candidate n...

Non-small cell lung cancer (NSCLC) is refractory to systemic chemotherapy, compared with small cell lung cancer. Until recently, only five drugs--cisplatin, vindesine, mitomycin, ifosfamide, and vinblastine--could produce overall response rates of 15% against NSCLC. However, recent efforts have contributed to the development of new drugs with activity against NSCLC, including irinotecan hydroch...

Lung cancer is the most common cause of cancer-related death worldwide and is classified into small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Several gene mutations that contribute to aberrant cell proliferation have been identified in lung adenocarcinoma, a part of NSCLC. Various anticancer drugs that target these mutated molecules have been developed for NSCLC treatment....

Lung cancer is the leading cause of mortality in the United States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Most NSCLC patients present with loco-regionally advanced or metastatic disease where response rates are low and median overall survival approximates 8 to 10 months. Chemotherapy is the mainstay of treatment for NSCLC patients with metastatic...

Worldwide, lung cancer is the leading cause of cancer death in men and has surpassed breast cancer as the leading cause of cancer death in women in the latter part of 1980s. It is estimated that more than 500 000 new cases are diagnosed each year; approximately 15–20% of lung cancer patients have small cell lung cancer (SCLC) and the other patients have non-small cell lung cancer (NSCLC), such ...

Lung cancer is the leading cause of cancer-associated mortality worldwide. Elucidation of the pathogenesis and biology of lung cancer is critical for the design of an effective treatment for patients. Non-small cell lung cancer (NSCLC) accounts for 80-85% of lung cancer cases. The abnormal expression of Notch signaling pathway members is a relatively frequent event in NSCLC. The Notch signaling...

Running Title: L1CAM in non-small cell lung cancer Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Purpose: Non-small-cell lung cancer (NSCLC) is a highly metastatic cancer with limited treatment options, thus requiring development of novel targeted therapies. Our group previously identified L1 cell adhesion molecule (L1CAM) express...

Objective: Histopathological overexpression of folate receptor-1 (FOLR1) involved in transport cell growth has been reported various cancers. Increased serum FOLR1(sFOLR1) also epithelial ovarian cancer. The aim was to investigate sFOLR1 levels non-small lung cancer (NSCLC) patients and the response prediction standard chemotherapy targeting folic acid metabolism.
 Method: In this prospect...

Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably de...